Chronic inflammatory and neuropathic pain are among the most common chronic conditions, but their treatment options present significant limitations both in efficacy and safety. Researchers from Purdue University presented data on their work aimed to develop adenyl cyclase type 1 (AC1, ADCY1) inhibitors as a new treatment for chronic pain.
Men with advanced prostate cancer only have a 5-year survival rate of 28%, mainly due to resistance to therapy. Enolase-1 (ENO1), also known as α-enolase, is a glycolytic enzyme with promise as a target for treating neuroendocrine prostate cancer (NEPC) and an alternative to prostate-specific member antigen (PSMA) targeting.
Akthelia Pharmaceuticals ehf and the University of Iceland have announced the successful joint award of a €6 million (US$6.6 million) EU Horizon Grant to fund the IN-ARMOR project that seeks to address antimicrobial resistance (AMR).
Tumor-associated calcium signal transducer 2 (TROP2) is a promising therapeutic target due to its high expression observed in several solid tumors. Investigators from Jiangsu Hengrui Pharmaceuticals Co. Ltd. have reported preclinical data on the anti-TROP2 antibody-drug conjugate (ADC) SHR-A1921 for the potential treatment of non-small-cell lung cancer (NSCLC).
At the ongoing AACR meeting, Amgen Inc. provided details on the discovery and preclinical characterization of AMG-305, a novel dual-targeting bispecific T-cell engager (BiTE) molecule, being developed as a potential new anticancer agent. While BiTE molecules offer a targeted immune therapy approach to treat cancer, on-target toxicity from normal tissue target expression has been a key issue in the development of T-cell engager molecules in solid tumors.
Heterogeneity, in both tumors and their microenvironment, limits the success of current cancer treatments. But it also provides opportunities. Heterogeneities “are not barriers to therapy, they are vulnerabilities to be exploited,” was how David DeNardo described his take at the 2023 annual meeting of the American Association for Cancer Research (AACR) on Sunday.
Additional early-stage research and drug discovery news in brief, from: Bioaegis Therapeutics, Evaxion Biotech, Jubilant Therapeutics, Sana Biotechnology.
Esophageal squamous cell carcinoma (ESCC) is a common malignant subtype of esophageal cancer that predominantly occurs in East Asian countries. Although genomic aberrations and highly mutated genes, such as TP53, have been identified in advanced stages, the first occurrence of mutations and their related effects during ESCC carcinogenesis remain poorly understood.
Bone remodeling involves a process of continuously cycling bone formation by osteoblasts balanced by resorption by osteoclasts. Development of osteoclast cells is initiated by RANKL and macrophage colony-stimulating factor (M-CSF) ligands leading to differentiation of bone marrow-derived monocytes (BMDMs) to generate osteoclast specified cells expressing TRAP, CTSK and MMP9.
Merck Sharp & Dohme Corp. have identified nicotinic α7 receptor positive allosteric modulators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, and schizophrenia.
RSS
